ValloVax: Legacy product

ValloVax is an angiogenesis-targeting immunotherapy made from placental endothelial cells and was approved by the FDA for clinical trials. It is the basis of all our therapeutics and is available in the US under the Right to Try Law.

FloraVax: Second Generation ValloVax

The patent for ValloVax lapsed and a new version was created using a special formulation with the FDA cleared drug RU-486. RU-486 unblocks immune suppression caused by cancer by working against the progesterone and glucocorticoid receptors. FloraVax has demonstrated superior activity to ValloVax and can be utilized under Right to Try in the US by licensed physicians.

StemVacs-V: Stem Cell Generated Third Generation ValloVax

Utilizing inducible pluripotent stem cell technology, Res Nova has developed and filed patents on a “universal donor” cellular immunotherapy which overcomes limitations of previous cell based products. StemVacs-V, which can be manufactured in an scalable and reproducible manner, is derived from one qualified cellular source, is optimized for the ability to stimulate immunity in cancer patients, many whom are already immune suppressed. StemVacs-V has demonstrated efficacy in animal studies.

FloraStilbene: Immunotherapy Adjuvant

Cancer immunotherapy represents an 8 billion dollar market. Many of these drugs require some level of pre-existing immunity before they are used. FloraStilbene is a proprietary combination of RU486 and Pterostilbene. It increases anti-cancer immunity.